High-throughput bio-layer interferometry (BLI) is revolutionizing the landscape of drug development, particularly in the realm of monoclonal antibody (mAb) discovery. This innovative technology allows researchers to efficiently assess biomolecular interactions, significantly accelerating the process of identifying viable drug candidates.
The Challenge of Antibody Development
Recently, Abveris, an antibody discovery specialist, faced a pressing challenge when a pharmaceutical company sought assistance in developing a high-affinity mAb for an imminent clinical trial. The tight timeline of just 11 weeks placed immense pressure on the team to deliver exceptional results. Anna Susi Brousseau, the team lead at Abveris, expressed confidence in their capabilities, highlighting a common issue faced by their partners: limited lead candidates from previous contract research organizations (CROs).
Leveraging the Octet Platform
Abveris’s success is attributed in part to its adept use of the Octet platform, manufactured by Sartorius. This system employs BLI technology to monitor biomolecular interactions without the need for labeling, thus enabling researchers to gather real-time data efficiently. The fluidic-free design and high throughput of the Octet platform allow for the simultaneous analysis of multiple samples, making it a powerful tool for antibody discovery.
Understanding BLI Technology
At its core, BLI operates by analyzing the interference pattern generated by white light reflected from a biosensor tip coated with immobilized proteins. As molecules bind to this surface, any variations in binding events result in shifts in the interference pattern, which are monitored in real time. This capability provides researchers with accurate insights into binding affinities, analyte concentrations, and the dynamics of molecular interactions.
Applications in Epitope Binning and Assay Development
BLI technology is particularly advantageous in epitope binning assays, which help determine the specific regions on target proteins to which antibodies bind. By enhancing the selection process for lead antibodies, researchers increase the likelihood of identifying candidates with desired biological activities. Furthermore, cross-competition assays identify mAbs binding to similar epitopes, which is crucial for developing biosimilars or biobetters. These applications extend to various assay types, including biomarker testing, where simultaneous binding of antibodies to an antigen is essential.
Advantages of Label-Free Measurement
One of the standout features of BLI is its label-free measurement capability, which eliminates the complications associated with traditional assays that require labels. This attribute allows for more accurate readings, as unbound molecules and environmental factors do not interfere with the results. Additionally, the ease of use associated with BLI technology accelerates the development and optimization of assays, making it a preferred choice for CROs focused on rapid turnaround times.
Accelerating Vaccine Research
Brousseau points to ongoing research efforts in developing a Hepatitis C vaccine as a prime example of BLI’s utility. In experiments, researchers utilize BLI to assess the binding of antibodies to viral components, providing critical data on binding specificity and interaction dynamics. Insights gained from such studies can inform therapeutic approaches and vaccine strategies, demonstrating BLI’s potential to influence diverse areas of drug development.
Comparison with Traditional Methods
Traditional methods, such as fluorescence-based assays and enzyme-linked immunosorbent assays (ELISA), often require extensive sample preparation and may not capture the full kinetic profile of interactions. In contrast, BLI’s ability to provide real-time, label-free monitoring not only simplifies the experimental process but also enhances the accuracy of data collected. Scientists can make informed decisions based on comprehensive analyses of dynamic interactions.
High-Throughput Capabilities
The scalability of BLI is another significant advantage, allowing for the parallel processing of up to 96 samples. This high-throughput capacity is especially beneficial for industry applications requiring multiple parameters to be assessed concurrently. Researchers can efficiently conduct titration series of interactions, facilitating quicker assay optimization and reducing the time needed to obtain results from days to mere hours.
Streamlined Processes and Cost Efficiency
BLI’s fluidic-free design minimizes the need for intricate cleaning processes between measurements, which reduces downtime and maintenance costs. This operational efficiency is particularly advantageous in core facilities where high user demand exists. The technology’s user-friendly nature ensures that researchers can focus on scientific discovery rather than logistical challenges.
Conclusion
High-throughput bio-layer interferometry is proving to be an indispensable tool in the drug development landscape. Its ability to streamline antibody discovery and enhance the efficiency of molecular interaction studies positions it at the forefront of biopharmaceutical research. As the demand for high-affinity molecules continues to rise, BLI will undoubtedly play a critical role in shaping the future of therapeutic development.
- Key Takeaways:
- BLI enables label-free, real-time monitoring of biomolecular interactions.
- The Octet platform enhances throughput and simplifies assay development.
- BLI is instrumental in epitope binning and therapeutic antibody selection.
- The technology accelerates research timelines and reduces costs.
- Its applications extend beyond antibodies to various molecular interactions essential for drug development.
Read more → www.nature.com